Menu Search
Equities

BioNexus Gene Lab Corp

HJ90:BER

BioNexus Gene Lab Corp

Actions
  • Price (EUR)0.00
  • Today's Change0.00 / 0.00%
  • Shares traded0.00
  • 1 Year change--
  • Beta--
Data delayed at least 15 minutes, as of Dec 30 1899.
More ▼
Improved Notifications for Markets Data Alerts
Improved Notifications for Markets Data Alerts
Want push notifications sent directly to your devices for equity price changes and breaking news stories? Let us know here.
 
Existing alertsView our existing alerts
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Profile data is unavailable for this security.

About the company

BioNexus Gene Lab Corporation is a Malaysia-based company, which provides ribonucleic acid (RNA)-based genomic diagnostics. The Company provides a molecular lab that is focused on the application of functional genomics to enable early detection of infectious diseases and cancers. The Company operates in the biochemical industry segment through its two Malaysian subsidiaries, MRNA Scientific Malaysia and Chemrex. MRNA Scientific Malaysia owns algorithm software, technology, and know-how related to the detection of common diseases through blood analysis which the Company uses in its business. The Company's non-invasive blood screening tests analyze changes in RNA to coronavirus, dengue, human immunodeficiency virus (HIV), human papillomavirus (HPV) and the risk potentiality of cancer diseases. Chemrex is a wholesaler of industrial chemicals for the manufacture of industrial, medical, appliance, aero, automotive, mechanical and electronic industries in Asean region.

  • Revenue in USD (TTM)9.78m
  • Net income in USD-2.66m
  • Incorporated2017
  • Employees30.00
More ▼
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.